Postmenopausal hormone replacement therapy and plasma lipoproteins

M. Taskinen
DOI: https://doi.org/10.1111/j.1365-2796.1995.tb01215.x
1995-11-01
Journal of Internal Medicine
Abstract:Cardiovascular diseases (CVD) are relatively uncommon in women before menopause but become the major cause of morbidity and mortality in postmenopausal women. What might be responsible for the loss of the protective effect of female sex against CHD in postmenopause I The deficiency of oestrogen after menopause is associated with unfavourable changes in lipid profiles, serum total and LDL cholesterol increase, and HDL cholesterol decreases. On the other hand, oestrogen replacement reverses these changes of lipoprotein profile [l]. Therefore, these adverse alterations of serum lipids in postmenopause are considered, with good reason, to contribute to the elevated CHD risk. In recent years, strong data has given evidence that postmenopausal hormone replacement therapy (HRT) reduces the coronary heart disease (CHD) risk by one-half [ 1. 21. Importantly, these favourable effects have been observed in studies where unopposed oestrogen has been used. Therefore, the cardioprotective effect is at least partially explained by beneficial changes of serum lipids induced by oestrogens. However, it has been estimated that the changes of lipoprotein profile cannot account for the entire cardiovascular protection provided by oestrogen replacement therapy in postmenopausal women [ 1. 21. Growing evidence indicates that oestrogens have favourable effects on vascular function by improving endothelium dependent vasodilation [3. 41. This action may contribute to the oestrogen-induced protection against CAD [ 3 1. In women with an intact uterus, the combination of progestin with oestrogen is mandatory for the reduction of the risk of endometrial hyperplasia and endometrial cancer. Consequently, most women are
What problem does this paper attempt to address?